Recombinant mouse el-glucuronidase administered intravenously to newborn mice with mucopolysaccharidosis type VII (MPS VII) is rapidly cleared from the circulation and localized in many tissues. Here we determine the tissue distribution of injected enzyme and describe its effects on the histopathology in 6-wk-old MPS VII mice that received either one injection of 28,000 U recombinant 5-glucuronidase at 5 wk of age or received six injections of 28,000 U given at weekly intervals beginning at birth. These mice were compared with untreated 6-wk-old MPS VII mice. The single injection decreased lysosomal distention in the fixed tissue macrophage system. MPS VII mice that received multiple injections had 27.8, 3.5, and 3.3% of normal levels of f-glucuronidase in liver, spleen, and kidney, respectively. Brain had detectable f-glucuronidase, ranging from 2.0-12.1% of normal. Secondary elevations of agalactosidase and fl-hexosaminidase in brain, spleen, liver, and kidney were decreased compared with untreated MPS VII mice. Although no improvement was observed in chondrocytes, glia, and some neurons, the skeleton had less clinical and pathological evidence of disease and the brain had reduced lysosomal storage in meninges and selected neuronal groups. These data show that recombinant f-glucuronidase treatment begun in newborn MPS VII mice provides enzyme to most tissues and significantly reduces or prevents the accumulation of lysosomal storage during the first 6 wk of life. Whether therapy begun later in life can achieve this level of correction remains to be established.
Introduction
Animal models oflysosomal storage disease have been used to test the efficacy of novel therapies for these diseases (1) (2) (3) . Treatments have included bone marrow transplantation (BMT),1 somatic cell gene therapy and enzyme replacement (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Mice homozygous for a frameshift mutation in the 1 . Abbreviations used in this paper: BMT, bone marrow transplantation; FTMS, fixed tissue macrophage system; Man 6-P, mannose 6-phosphate; MPS, mucopolysaccharidosis.
fl-glucuronidase gene, Gus, (14) have murine mucopolysaccharidosis type VII (MPS VII) ( 1, 2) and share many biochemical, pathological, and clinical features with human MPS VII (Sly Syndrome) ( 15) . An increased life span and reduction in lysosomal storage in many tissues was observed in MPS VII mice after BMT (4) . Newborn mice pretreated with low-dose radiation followed by BMT showed improved skeletal development and had f3-glucuronidase positive cells in the brain (5) . A reduction of lysosomal storage was also observed in the liver and spleen of MPS VII mice receiving retroviral mediated somatic cell gene therapy (9) (10) (11) . Although BMT therapies correct or prevent lysosomal storage, they require pretreatment with irradiation to ensure transplant engraftment. Treatment of newborns with BMT, although effective, is accompanied by radiation dose-dependent cerebellar and retinal dysplasia and long bone growth retardation (5) . A method of delivering enzyme that did not require irradiating young animals might allow reduction in lysosomal storage without the side effects observed with BMT.
Since the mannose receptor is expressed on the surface of tissue macrophages, purified glucocerebrosidase enzymatically modified in vitro to expose mannosyl residues ( 16) is targeted to the fixed tissue macrophage system (FTMS). Although a recent report showed that only a small fraction ofthe currently licensed enzyme was actually targeted to macrophages ( 17) ( 1) . Animals for this study were from either a pedigreed colony, maintained by strict brother-sister matings, or a nonpedigreed colony, maintained by crossing heterozygotes obtained from the pedigreed colony. The offspring were never more than one generation from the pedigreed colony. Homozygous mutants and normals (+ / +) were distinguished from heterozygotes (+IgunPs) at birth using a fluorometric assay (26) to determine the level of(-glucuronidase activity in a sample of tissue obtained by toe clipping. Animals were observed weekly for phenotypic evidence of MPS VII.
Enzyme production and purification. Man 6-P receptor deficient mouse L cells (27) which secrete 70% oflysosomal enzymes with the phosphomannosyl recognition marker were stably transfected with an expression plasmid containing the mouse f3-glucuronidase cDNA ( 19, 28) . f3-glucuronidase was purified from the conditioned media by ammonium sulfate precipitation, sephadex, and ion exchange chromatography ( 19 Naohthol-AS-BI-,8glucuronidase X62.5; (B, D, and F) toluidine blue, X242.
rib, liver, kidney, spleen, heart, aorta, and a transverse section of the cerebrum including cerebral cortex, hippocampus, cerebellum, and leptomeninges were examined. Stifel joints were also examined after paraffin embedding and routine processing and staining with hematoxylin and eosin as well as with colloidal iron (2) . Tissues from untreated mutant and normal mice from this and previous studies (2, 4, 5) were used as histological controls.
P-glucuronidase was identified histochemically in unfixed frozen sections of rib, liver, spleen, kidney, heart, and brain using naphthol-AS-BI-t-D-glucuronide and pararosaniline hydrochloride with a 3-h preincubation at 4VC in substrate alone and a 4-h incubation at 37'C in the presence of substrate and pararosaniline hydrochloride (30) . Morphometric analyses were performed on the femur, humerus, radius, ulna, tibia, and fibula from treated and untreated mice as previously described (5) . Briefly, the long bones were excised, radiographed with a Hewlett Packard Faxitron specimen analyzer, and measured at their longest aspect. Bone lengths were then grouped and compared according to treatment and sex. The bone lengths for the treated group, represented as percent untreated normal, were averaged and analyzed using the Student's t test of statistical significance. 
Results
Biochemical response ofMPS VII mice to recombinant f3-glucuronidase Enzyme distribution. 1 wk after the last injection, f3-glucuronidase was detected in the liver, spleen, kidney, and brain of animals that received either single or multiple injections of enzyme (Fig. 1) . The livers of animals that received a single injection had 35% ofnormal enzyme activity. Livers ofanimals that received multiple injections had 27.8% of normal enzyme activity. Spleens and kidneys had 3-5% of normal levels of enzyme. The brains of animals receiving multiple injections had an average level of enzyme activity that was 6.7% of normal. However, in the brains of animals that received a single injection at 5 wk of age, the average activity level was only 1% of normal 1 wk after the injection. Except for the brain, the tissues from the two normal animals receiving multiple injections showed no detectable increases in f3-glucuronidase activity. 3-glucuronidase activity was not detected in the mutant animal injected with enzyme dilution buffer alone.
Secondary enzyme elevations. a-galactosidase and f3-hexosaminidase returned to near normal levels in the liver, spleen, and kidney of mutant mice receiving multiple injections (Fig.  2) . There was a significant decrease in the levels of both enzymes (P < 0.05) in the brains of the mice from the multiple injection group. The spleens from animals injected with a single dose ofenzyme also had nearly normal levels ofa-galactosidase and f3-hexosaminidase. In contrast, the livers and kidneys showed only moderate decreases in the secondary elevations of a-galactosidase and f3-hexosaminidase in response to a single enzyme injection and the brain showed little or no change. As expected, the levels of a-galactosidase and I-hexosaminidase in normal mice receiving six enzyme injections remained at normal levels (Fig. 2) and the mutant animal receiving six injections of dilution buffer without enzyme had secondary elevations similar to untreated mutant animals (data not shown).
Reversal of lysosomal storage disease following enzyme replacement therapy Clinically, the MPS VII mice treated from birth with six enzyme injections were difficult to distinguish from normal mice at 6 wk of age. They had nearly normal body weights and reduced facial dysmorphism (documented radiographically below). However, the mice receiving only a single enzyme injection at 5 wk ofage were phenotypically identical one wk later to untreated MPS VII mice of the same age.
Uninjected adult MPS VII mice had no histochemically detectable fl-glucuronidase (Fig. 3 A) and the cytoplasm of their Kupffer cells and the hepatocytes contained numerous distended lysosomes (Fig. 3 B) . 1 wk after a single injection of enzyme, f3-glucuronidase was detectable histochemically in the liver of mutant mice (Fig. 3 C) (Fig. 3 E) . Hepatic lysosomal distention was absent in mice that received multiple injections of enzyme (Fig. 3 F) . The spleens from both the singly and multiply injected MPS VII mice also showed marked clearing of lysosomal storage. In mice treated with multiple fl-glucuronidase injections, interstitial cells in the heart and the kidney, glomerular visceral epithelial cells, and retinal pigment epithelium had less lysosomal storage than untreated MPS VII mice. However, fl-glucuroni- dase activity was not detected histochemically in the heart or kidney after six enzyme injections, and the corneal stromal fibroblasts and cells in the aortic media had persistent lysosomal storage.
There was microscopic (Fig. 4) and radiographic ( Fig. 5 ) evidence of partial correction in bones after multiple enzyme injections. The osteoblasts lining the bone had less lysosomal distention as did the sinus lining cells, and bone marrow from the one mouse examined was positive for f3-glucuronidase activity by histochemical stain. However, the chondrocytes contained distended lysosomes and were indistinguishable from those of untreated mutants and there was persistent articular storage. The bone length in MPS VII mice which received multiple injections was 88% of normal compared with 82% of normal in untreated mutants (data not shown). Radiographic evidence of MPS was also reduced in mice receiving six enzyme injections (Fig. 5) . In contrast, mice receiving only a single injection of fl-glucuronidase had bones indistinguishable from those ofuntreated MPS VII mice, except that the marrow sinus lining cells had reduced lysosomal storage. Within the brain, the ependyma, leptomeninges, perivascular cells, and specific neuronal groups had a decrease in lysosomal storage following the six weekly injections of recombinant ,B-glucuronidase ( Fig.  6 ; Table I ). However, Purkinje and glial cells contained persistent lysosomal storage indistinguishable from that observed in untreated MPS VII controls (Table I ). All neuronal groups in the central nervous system of mice that received a single injection of enzyme at 5 wk of age failed to show improvement in lysosomal storage (Table I) .
Discussion
We recently reported that recombinant ,B-glucuronidase was widely distributed in tissues ofnewborn MPS VII mice 1 h after A C intravenous infusion (20) . The distribution correlated generally with the distribution of the Man 6-P receptor. Especially striking were the observations that heart, liver, and brain had 23, 13.5, and 0.3 times, respectively, the levels of f3-glucuronidase found in normal mice, and that bone had abundant histochemically demonstrable fl-glucuronidase activity. The present study demonstrates that recombinant enzyme reaching these tissues has important therapeutic effects in preventing the accumulation of lysosomal storage and thereby delaying, if not preventing, the clinical consequences of f3-glucuronidase deficiency.
We previously showed that BMT in young adult mice at 4-8 wk ofage dramatically altered the clinical course ofmurine MPS VII, increasing life span from an average of 5 mo to an average of 18 mo, and correcting metabolic defects in liver, spleen, heart, cornea, and meninges (4). Skeletal improvement was not readily apparent, probably because bone disease was already well established at the time the adult animals received BMT. Also, in contrast to the results seen with enzyme replacement, no decrease in neuronal storage was observed after BMT. We subsequently studied the effects of BMT in newborn MPS VII mice (5) . Tissue responses were at least as good as when BMT was given to adults, and the animals had less facial dysmorphism and other clinical signs of lysosomal storage disease compared to animals that received BMT later in life. However, the radiation used to ablate the newborn marrow had deleterious effects on development of the cerebellum and retina, and on the growth of long bones.
The extremely favorable response to enzyme therapy seen in the present study suggests that enzyme therapy may reach tissues that BMT does not. To achieve maximum levels ofcorrection may require early administration of enzyme to reach these tissues during critical developmental stages early in life. In addition, because complete bone marrow engraftment takes 4-6 wk (31 ), enzyme replacement both prior to and immediately after transplantation may substantially improve the longterm therapeutic benefits of BMT.
These studies show that recombinant enzyme replacement therapy achieves improvements in the developing central nervous system that were not achieved by BMT in newborns or young adults. Several possible factors may contribute to this advantage of early enzyme therapy. First, the distribution of cell surface receptors which influence where enzyme localizes is known to be subject to developmental regulation (21-23). The Man 6-P receptor represents 0.1% of the total protein in fetal rat brain and falls 5-10-fold during postnatal development.
The second factor is that the blood/brain barrier may not be completely developed in the newborn mouse (32) . This may provide intravascular f3-glucuronidase access to cell surface receptors in the central nervous system that are not accessible subsequently. In addition, the relatively large dose in the newborn (7 mg/kg) may influence the distribution by mass action and by saturating competing receptors (e.g., the mannose receptor in the FTMS). In the experiments reported here, the amount of enzyme given at 5 wk (28,000 U) was the same as the amount given to the newborn. Thus, compared to a newborn, the 5-wk-old received only 1/10th the dose per kg due to the large increase in weight with age.
The difference in distribution of -glucuronidase in livers from singly or multiply injected MPS VII mice is also of interest. This may relate to differences in developmental regulation of various cell surface receptors in liver (e.g., the asialoglycoprotein receptor on hepatocytes (33) , the mannose receptor on Kupffer cells (24, 25) , and the Man 6-P receptor (34, 35) on both cell types), and might also be influenced by the changing weight-dependent dosage received over the course ofthe injections. It will be interesting to determine the distribution of the enzyme when a weight adjusted dose comparable to that given in the newborn is administered to the 5-wk-old adult animal.
While there are still questions to be answered about the optimum dose and regimen for enzyme injections, the general conclusion from these studies is that enzyme therapy for MPS VII beginning in the newborn period is extremely encouraging. It is now important to compare the long-term effects ofenzyme replacement on survival and clinical course in animals receiving enzyme therapy as a sole treatment, or in combination with BMT, to the favorable clinical responses reported for BMT alone.
